When will the FDA reclassify BPC 157 to Category 1? Odds & Predictions The trend of unproven peptides is spreading through influencers and RFK Jr. allies CNN The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York BPC 157 and TB 500: Injury Healing Peptides Jonathan L. Glashow posted on the topic LinkedIn